AI-powered microscope brings a new tool to the fight against cancer
Shane McGlaun - Dec 18, 2020, 5:57am CST
Researchers at Rice University and the University of Texas MD Anderson Cancer Center have announced a new microscope powered by AI. The researchers believe the AI-powered microscope could check cancer margins in minutes. When surgeons have to remove cancer, the biggest question is, did they get it all, and the margins are examined in detail to determine if all the cancer was removed. The new microscope was created to quickly and inexpensively examine large tissue sections, potentially during surgery, to discover that critical answer.
email article
Myelofibrosis is a rare blood cancer that disrupts the body s normal production of blood cells and causes extensive scarring the formation of fibrous tissue in the bone marrow.
It belongs to a group of diseases known as myeloproliferative neoplasms (MPNs), which also includes essential thrombocythemia (ET) and polycythemia vera (PV). Myelofibrosis can occur on its own, or develop as a natural evolution of ET and PV.
According to the Leukemia & Lymphoma Society, myelofibrosis occurs in about 1.5 per 100,000 people in the U.S. annually, and although it may present in patients of any age, it is more likely to be diagnosed in people over the age of 50.
AI-powered microscope could check cancer margins in minutes miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Dr. Catherine Van Poznak is the co-chair of a new SWOG Cancer Research Network trial that details, for the first time, the incidence of a common bone disease in cancer. view more
Credit: University of Michigan Rogel Cancer Center
PORTLAND, OR - A landmark study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has found that 2.8 percent of patients on average develop osteonecrosis of the jaw, or ONJ, within three years of starting a common treatment for cancer that has spread to the bone.
A new startup is working towards using a patient’s own genetic makeup to fight cancer.
Catamaran Bio, a startup at LabCentral in Cambridge, was established to consider the potency of natural killer (NK) cells in fighting cancer, and so far, it has raised $42 million from five venture capital companies including the founding investor, SV Health Investors, of Boston.
“This was a group of people who had wanted to do something together for a long time,” said Houman Ashrafian, managing partner of SV Health Investors.
Immunotherapy drugs such as Kymriah, Novartis’s leukemia therapy, have shown promising results for the treatment of blood cancers. The approach, also called CAR-T therapy, relies on harvesting patients’ T cells and genetically altering them to target the cancer after they are reintegrated into the patient’s genetic makeup. Earlier in 2020, researchers at MD Anderson Cancer Centre announced they achieved a “73% response rate with a CD19-targeting therapy d